Update on medical treatment for Cushing’s disease

[1]  E. Oldfield,et al.  Cushing's disease: pathobiology, diagnosis, and management. , 2017, Journal of neurosurgery.

[2]  M. Fleseriu,et al.  Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study , 2016, Endocrine.

[3]  Jacques Young,et al.  Long-term (19-month) control of urinary free cortisol with osilodrostat in patients with Cushing's disease: results from an extension to the LINC-2 study , 2016 .

[4]  M. Fleseriu,et al.  Medical treatment of Cushing's Disease. , 2016, Minerva endocrinologica.

[5]  L. Nieman,et al.  Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report. , 2016, The Journal of reproductive medicine.

[6]  L. Vilar,et al.  The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study , 2016, International journal of endocrinology.

[7]  M. Komada,et al.  The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. , 2016, European journal of endocrinology.

[8]  A. Grossman,et al.  Therapeutic Strategies for the Treatment of Severe Cushing’s Syndrome , 2016, Drugs.

[9]  F. Karlsson,et al.  Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients. , 2015, European journal of endocrinology.

[10]  Jacques Young,et al.  Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease , 2015, Pituitary.

[11]  H. Kushner,et al.  Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension , 2015, BMC Endocrine Disorders.

[12]  Julian R. E. Davis,et al.  Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. , 2015, The Journal of clinical endocrinology and metabolism.

[13]  L. Nieman,et al.  Cushing's syndrome , 2015, The Lancet.

[14]  P. Hoffmann,et al.  Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. , 2015, Toxicology and applied pharmacology.

[15]  A. Tabarin,et al.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[16]  J. Newell-Price,et al.  Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome. , 2015, European journal of endocrinology.

[17]  A. Grossman,et al.  Emerging drugs for Cushing’s disease , 2015, Expert opinion on emerging drugs.

[18]  S. Melmed,et al.  Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease. , 2015, The Journal of clinical endocrinology and metabolism.

[19]  P. Chanson,et al.  Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. , 2015, European journal of endocrinology.

[20]  F. Ceccato,et al.  Clinical use of pasireotide for Cushing’s disease in adults , 2015, Therapeutics and clinical risk management.

[21]  C. Simeoli,et al.  The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center , 2015, Endocrine.

[22]  A. Colao,et al.  Cabergoline use for pituitary tumors and valvular disorders. , 2015, Endocrinology and metabolism clinics of North America.

[23]  T. Wieland,et al.  Mutations in the deubiquitinase gene USP8 cause Cushing's disease , 2014, Nature Genetics.

[24]  G. Arnaldi,et al.  Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations , 2015, Pituitary.

[25]  N. Tritos,et al.  Update on radiation therapy in patients with Cushing’s disease , 2015, Pituitary.

[26]  M. Fleseriu,et al.  Medical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers , 2015, Pituitary.

[27]  J. Bertherat,et al.  Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial , 2014, Pituitary.

[28]  M. Fleseriu,et al.  Treatment of Cushing's disease: a mechanistic update. , 2014, The Journal of endocrinology.

[29]  J. Schopohl,et al.  Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study , 2014, Clinical endocrinology.

[30]  M. Buchfelder,et al.  Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. , 2014, The Journal of clinical endocrinology and metabolism.

[31]  M. Fleseriu,et al.  Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. , 2014, Journal of molecular endocrinology.

[32]  M. Fleseriu,et al.  Study Design of a Phase II trial of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease , 2014 .

[33]  X. Bertagna,et al.  LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. , 2014, The Journal of clinical endocrinology and metabolism.

[34]  G. Golor,et al.  Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. , 2014, Diabetes research and clinical practice.

[35]  P. Zelissen,et al.  Increased long‐term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease , 2014, Clinical endocrinology.

[36]  P. Chanson,et al.  Ketoconazole in Cushing's disease: is it worth a try? , 2014, The Journal of clinical endocrinology and metabolism.

[37]  G. Braunstein,et al.  Global clinical response in Cushing’s syndrome patients treated with mifepristone , 2014, Clinical endocrinology.

[38]  A. Lacroix,et al.  Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial , 2014, Pituitary.

[39]  G. Vitale,et al.  Molecular basis of pharmacological therapy in Cushing’s disease , 2014, Endocrine.

[40]  L. Denaro,et al.  Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? , 2014, Pituitary.

[41]  F. Casanueva,et al.  Managing Cushing’s disease: the state of the art , 2014, Endocrine.

[42]  Ritu Malik,et al.  Metyrapone for Long-Term Medical Management of Cushing's Syndrome , 2013, Case reports in endocrinology.

[43]  S. Schulz,et al.  Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. , 2013, The Journal of clinical endocrinology and metabolism.

[44]  L. Nieman.  Update in the medical therapy of Cushing's disease , 2013, Current opinion in endocrinology, diabetes, and obesity.

[45]  S. Mudaliar,et al.  Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. , 2013, The Journal of clinical endocrinology and metabolism.

[46]  F. Casanueva,et al.  Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations , 2013, Pituitary.

[47]  L. Katznelson.  Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. , 2013, The Journal of clinical endocrinology and metabolism.

[48]  M. Fleseriu,et al.  A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[49]  P. Chanson,et al.  Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. , 2012, Diabetes & metabolism.

[50]  J. Romijn,et al.  Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing’s disease , 2013, Pituitary.

[51]  M. Fleseriu,et al.  Mifepristone: is there a place in the treatment of Cushing’s disease? , 2013, Endocrine.

[52]  F. de Jong,et al.  Fluconazole inhibits human adrenocortical steroidogenesis in vitro. , 2012, The Journal of endocrinology.

[53]  I. Gich,et al.  A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome , 2012, Clinical endocrinology.

[54]  W. Drake,et al.  Etomidate in the emergency management of hypercortisolemia. , 2012, European journal of endocrinology.

[55]  J. Bertherat,et al.  Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. , 2012, European journal of endocrinology.

[56]  I. Shimon,et al.  Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review , 2012, Pituitary.

[57]  E. Arvat,et al.  Potential role for retinoic acid in patients with Cushing's disease. , 2012, The Journal of clinical endocrinology and metabolism.

[58]  M. Fleseriu,et al.  Medical management of Cushing’s disease: what is the future? , 2012, Pituitary.

[59]  A. Grossman,et al.  Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. , 2012, European journal of endocrinology.

[60]  M. Fleseriu,et al.  Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. , 2012, The Journal of clinical endocrinology and metabolism.

[61]  A. Colao,et al.  A 12-month phase 3 study of pasireotide in Cushing's disease. , 2012, The New England journal of medicine.

[62]  J. Briegel,et al.  Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate , 2012, Pituitary.

[63]  A. Mamelak,et al.  EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. , 2011, The Journal of clinical investigation.

[64]  M. Culler.  Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors , 2011, Hormone and Metabolic Research.

[65]  P. Chanson,et al.  Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. , 2011, The Journal of clinical endocrinology and metabolism.

[66]  Shuo Lin,et al.  Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor , 2011, Proceedings of the National Academy of Sciences.

[67]  N. Tritos,et al.  Management of Cushing disease , 2011, Nature Reviews Endocrinology.

[68]  B. Ploeger,et al.  Mitotane has a strong and a durable inducing effect on CYP3A4 activity. , 2011, European journal of endocrinology.

[69]  D. Schteingart.  Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism , 2011 .

[70]  W. Ludlam.  Medical Treatment of Cushing's Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone , 2011 .

[71]  A. Lacroix,et al.  Cabergoline monotherapy in the long-term treatment of Cushing's disease. , 2010, European journal of endocrinology.

[72]  J. Ménard,et al.  Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism , 2010, Hypertension.

[73]  T. Brue,et al.  Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone , 2010, Neuroendocrinology.

[74]  J. Romijn,et al.  Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. , 2010, The New England journal of medicine.

[75]  A. Klibanski,et al.  Delayed remission after transsphenoidal surgery in patients with Cushing's disease. , 2010, The Journal of clinical endocrinology and metabolism.

[76]  L. Vilar,et al.  Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease , 2010, Pituitary.

[77]  P. Chanson,et al.  Merits and pitfalls of mifepristone in Cushing's syndrome. , 2009, European journal of endocrinology.

[78]  G. Lombardi,et al.  Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing's disease partially responsive to monotherapy with cabergoline , 2009 .

[79]  J. Romijn,et al.  Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. , 2009, The Journal of clinical endocrinology and metabolism.

[80]  P. Cappabianca,et al.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. , 2009, The Journal of clinical endocrinology and metabolism.

[81]  Y. Wang,et al.  Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. , 2009, The Journal of clinical endocrinology and metabolism.

[82]  S. Lamberts,et al.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome , 2009, Reviews in Endocrine and Metabolic Disorders.

[83]  L. Nieman,et al.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. , 2008, The Journal of clinical endocrinology and metabolism.

[84]  A. Ahmann,et al.  Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. , 2008, Clinical therapeutics.

[85]  B. Allolio,et al.  Mifepristone (RU 486) in Cushing's syndrome. , 2007, European journal of endocrinology.

[86]  M. Fleseriu,et al.  Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful , 2007, Current opinion in endocrinology, diabetes, and obesity.

[87]  H. Hammes,et al.  Long-Term Treatment of Central Cushing's Syndrome with Rosiglitazone , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[88]  I. Lancranjan,et al.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas , 2001, Endocrine.

[89]  F. Holsboer,et al.  Retinoic acid as a novel medical therapy for Cushing's disease in dogs. , 2006, Endocrinology.

[90]  W. Schima,et al.  Long term control of hypercortisolism with fluconazole: case report and in vitro studies. , 2006, European journal of endocrinology.

[91]  E. Arvat,et al.  Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease , 2006, Clinical endocrinology.

[92]  L. Nieman,et al.  Cushing's syndrome , 2005 .

[93]  L. Nieman,et al.  Cushing’s Syndrome , 2019, Canadian Family Practice Guidelines.

[94]  C. Brain,et al.  Efficient Short-Term Control of Hypercortisolaemia by Low-Dose Etomidate in Severe Paediatric Cushing’s Disease , 2005, Hormone Research in Paediatrics.

[95]  D. Hoyer,et al.  Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. , 2005, American journal of physiology. Endocrinology and metabolism.

[96]  F. Trimarchi,et al.  Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. , 2004, European journal of endocrinology.

[97]  J. Kros,et al.  Dopamine receptor expression and function in corticotroph pituitary tumors. , 2004, The Journal of clinical endocrinology and metabolism.

[98]  G. Fava,et al.  Effect of the Serotonin Antagonists Ritanserin and Ketanserin in Cushing's Disease , 2000, Pituitary.

[99]  A B Atkinson,et al.  Diagnosis and complications of Cushing's syndrome: a consensus statement. , 2003, The Journal of clinical endocrinology and metabolism.

[100]  J. Jørgensen,et al.  Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo , 2001, Journal of endocrinological investigation.

[101]  R. Reznek,et al.  Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. , 1998, The Journal of clinical endocrinology and metabolism.

[102]  M. Buchfelder,et al.  Octreotide exerts different effects in vivo and in vitro in Cushing's disease. , 1994, European journal of endocrinology.

[103]  N. Shimizu.  [Cushing's disease]. , 1993, Nihon rinsho. Japanese journal of clinical medicine.

[104]  A. Grossman,et al.  Short and long‐term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome , 1991, Clinical endocrinology.

[105]  S. Lamberts,et al.  Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). , 1991, Annals of internal medicine.

[106]  B. Allolio,et al.  Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. , 1990, The Journal of clinical endocrinology and metabolism.

[107]  X. Bertagna,et al.  Transient inhibition of RU 486 antiglucocorticoid action by dexamethasone. , 1990, The Journal of clinical endocrinology and metabolism.

[108]  J. Loeffler,et al.  Ketoconazole inhibits corticotropic cell function in vitro. , 1988, Endocrinology.

[109]  A. Henniker,et al.  THE EFFECT OF o,p'‐DDD ON ADRENAL STEROID REPLACEMENT THERAPY REQUIREMENTS , 1987, Clinical endocrinology.

[110]  X. Bertagna,et al.  Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. , 1986, The Journal of clinical endocrinology and metabolism.

[111]  X. Bertagna,et al.  The new steroid analog RU 486 inhibits glucocorticoid action in man. , 1984, The Journal of clinical endocrinology and metabolism.

[112]  J. Ratcliffe,et al.  DIRECT IN VITRO INHIBITION OF ADRENAL STEROIDOGENESIS BY ETOMIDATE , 1983, The Lancet.

[113]  D. Feldman,et al.  Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. , 1983, The Journal of clinical investigation.

[114]  S. Lamberts,et al.  Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. , 1982, The Journal of clinical endocrinology and metabolism.

[115]  N. Shimizu.  [Treatment of Cushing's disease]. , 1978, Nihon rinsho. Japanese journal of clinical medicine.

[116]  H. Cushing.  The basophil adenomas of the pituitary body. , 1932, Annals of the Royal College of Surgeons of England.

[117]  W. Manderson.  Q fever; report of a case. , 1949, Lancet.